SIMPLA

Información principal

  • Denominación comercial:
  • SIMPLA 150 mg COMPRIMIDOS RECUBIERTOS
  • Dosis:
  • 150 mg
  • formulario farmacéutico:
  • COMPRIMIDO RECUBIERTO
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • LABORATORIOS VARGAS, S.A.

Documentos

Localización

  • Disponible en:
  • SIMPLA 150 mg COMPRIMIDOS RECUBIERTOS
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.36.280
  • Fecha de autorización:
  • 20-06-2007
  • última actualización:
  • 03-09-2018

Prospecto

sterio

del Poder

Popular

REGISTRO NACIONA¡ DE PRODUCTOS

TARMACEOTlCOS

0 7 2 t '

DRA.

CAF!,IEN

EC¡]ANIQIT€,

De acuerdo con dict¿men de 1a

fa¡nacéuticos,

sesión

N"

2A/A6/2AA1,

ap¡ueba el

p ¡ o d n c t ó

RECUB¡ERTOS

SREF-05-OA3O.

21[?

J!¡ta

Revisora de P¡odúctos

Acia

9026

i é c h a

FEl,loRE!

150 ng

E . F . 3 6 . 2 3 0

" b

e ) ,

p c - o

ó ó

d É

ó d .

aarnacéuticos,

1a ¡eco¡side¡ació¡

de las

exigencias

s e n a l a d a s

cónp¡óniso

dé cónu¡icar

G¡énio

Médicó

1ó siguiente:

rest¡icciones

de uso:

¿ r d

p , o d ó

¿ o

a o l

s P o s

p . ! d

Adultos;

150 ng una

n e s ,

No se

ádninist¡e

duranté

é¡barazó

cuandó se

sósp€che

exlste¡cia/

du¡ante

lacta¡cia.

caso

s e ¡

( e - ¿ ! é L r ¡ c ¿

. u s p é r d ? ¡ e

d e r ' 1

v ¿ _

e r e

d_be ev'-

d e . r ¡

d . . ¿ . t e

p ó

e r o s

e d o

o - d

r u e q ó

d É

"

ingesta

dé1 nedicmento.

lrdt¿¡,e¡t.

o ¡

Co¡tlai¡di

€cio¡és

¡rpe¡se¡slbilldad

a los

conlonentes de la

f ó l h u l a .

2006

AÑO

BCENTEMRO

JURAMENÍO

GENERAL

SIMO

FMNC]SCO

¡¡IRANOA

PARTICIPACION

PROTAGON

CAY OEL

PODER

POPULAR

Min¡sle

o del Poder

Popula¡

¡¡GISTRO

NACIONAI

PRODUCTOS

¡a¡¡,facluTIcos

Rea..iones

Adv€¡éás:

' , n o - o 1 -

p s e - o ó o

. é ,

é , d

- " 1 7 é d a

o Ó .

r - ó b ! ó ¡

ó f q

ó d ¡

nialqias/

dólo¡

óseo

s u d o r a c l ó n .

Ament.

enzinas

hepáticas/

hilocalcenia,

h i p o f o s

fatenia

hipónaqnesenia,

esoiaqitis,

qast¡itis,

ú l c e r a s

!ast¡olhtestinales,

aste¡ia,

nldro¡ef¡osis¡

edema

p u l n o

¡a¡itidina,

Ie.h€

y yogourt.

se 1e asigna

Fróducto

!e¡iodo

d€

laIidéz

t é n t a t i v o

(02)

anós

envasado

BLISTf,R

P¡/c/

FO¡L

AI-UMINIO, cón

e1 cónpromiso

réhiti¡

condiciones

r:enpe¡atura

nñedad

¡elativa

sús

respectivas

óscilaciones

resultádos

a¡aliticos

e s t a b i l i d a d

para

tres

prin€ros

lotes

cofrerciales

cada

t r e s

1:l)

néses durante

¡iner

anó

cada

sers

ñ e s e s

du¡ante

segúndo

añó

dél

period.

validez

asig¡ado,

almacenado bajo

cóndiciones

cLinátices

dé v€nezuela

1 : 0 . c 1 2 . C / r 0 1 1 5 i H R t ,

corregi¡

fó¡m!la

.na1i

cuantitativa,

indicando

I o s

tableta,

po¡centajes

tóna¡do

crenta

1a canticac

IBANDRoNATo

MoNosoDrco ¡NHrDRo ¡tilizado

!a!á

élabóra¡

cio¡es

4 cómprimidos Re.utiie.tos.

acepta

presentaclón

cohprrmdós

Recx

bie¡tós

ya qne

e:cederia

peliodo

v a l i d e z .

empáque

u¡idad

posológ!ca

segrln

p¡ospecto

lnternó

según

nodelo

a¡ero

cohdiciones

¡est¡iccic¡es

i s o

.2006

AÑO

BICENfENARIO

OELJIJRAI¡ENTO

GENERALLSIIT¡O

FMNC SCO

DE MIMNOA

Y DE LA PARTIC

PACION

PROTAGON

CAY DEL

PODER

POPULAR'

nonb e

q-'é'

c ó

. é

, ó

. . : é L ! i a 1 : z a c : ó n

d e b e

- e ' - ó

p ¿ . -

¿ ó ' ¿

: ó r . d - l

p d l

defecto

patrón

p¡inario

" I b a ¡ d r ó n a t ó

Monosódico

Anhidró"

lara

aplicar

netodoloqla

é¡viada

pór

cromatóg¡afia

¡iquida

a l t a

SdfilH::Bfl*''""

M nist€rio

d€lPoder

Populá¡

REGISTRO

NACIONAI- DE IRODUCTOS

FAR¡IAC'UTICOE

C _ o . ! r n -

o - r

"

o d e l

A r - , ( u r o 6 0 d é

RegleenEo

l,ey

<le1

Ejerclcio

aa¡nacia

viqenie,

publicadó

en cacéta

oficial

Nó.

4.532

e x t r a o ¡

n " _ I o - n " r o o - 1 9 9 ) .

obliqados

participar

Junta

Revisorá

P¡odlctós

¡ármácéuticós,

fecha en lá

cual

s€ i¡icie

1á c.ne¡cia

an-ra

qué

fuhcio¡a¡ios

ac¡editados

Instituto

Nacional

Higle¡e

"

Rafael

Range1

",

puedan

proceder

á capta¡

l a s

muest¡as

.ór¡espondientes

eD e1

propio

sttio

f a b r t -

; ó n ,

r : b

: ó n

o d ! . l o ,

o-aoo

cÓ_p-Ó-

se¡á sancionádc co¡

p¡óhibr.ió¡

p ¡ ó d u c t ó ,

- - t € e

" r e

álro¡ado

p ¡ o d u c t o .

JUNTA

RIVISO

ni/U

2006 AÑO

BICENTENAR

DELJUMi'ENTO DEL

GENERALIS]i/IO

FMNCISCO

M MNDA

Y DE LA PARTCIPACON

PROTAGONICAY

PODER

POPIJLAR'

15-11-2018

Drug Safety Update , Noviembre 2018

MHRA , 14 de noviembre de 2018 Hidroclorotiazida: riesgo de cáncer de piel no melanoma Sildenafil: hipertensión pulmonar persistente del recién nacido Fluoroquinolonas: aneurisma y disección aórtica

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

12-11-2018

La vitamina D cuida tu corazón

La vitamina D cuida tu corazón

La tasa de la vitamina D en el cuerpo humano es uno de los factores más importantes que influyen en el funcionamiento del corazón y el sistema vascular, así como la capacidad para soportar la actividad física, según científicos estadounidenses. En los últimos años se ha descubierto que esta vitamina reduce la probabilidad de morir […]

Cuba - infomed - Red de Salud de Cuba

10-11-2018

Dengue en embarazo puede causar problemas neurológicos

Dengue en embarazo puede causar problemas neurológicos

La infección por el virus del dengue durante el embarazo puede aumentar en un 50 por ciento el riesgo de anomalías congénitas neurológicas en el recién nacido y en cuatro veces el de otras malformaciones cerebrales, según un reciente estudio. Este nuevo hallazgo se suma a dos descubrimientos anteriores de los mismos investigadores de la […]

Cuba - infomed - Red de Salud de Cuba

10-11-2018

Descubren a través de la proteína MASTL el origen de la trombocitopenia causada por un oncogen

Descubren a través de la proteína MASTL el origen de la trombocitopenia causada por un oncogen

El Grupo de División Celular y Cáncer del Centro Nacional de Investigaciones Oncológicas (CNIO) ha descubierto que MASTL, proteína cuyo papel en el organismo es aún poco conocido, tiene una importante función de control del citoesqueleto, la estructura que da forma a las células y condiciona su movilidad y capacidad de agrupación. Los investigadores han […]

Cuba - infomed - Red de Salud de Cuba

9-11-2018

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of polyacrylic acid, sodium salt, cross‐linked, FCM substance No 1015, which is intended to be used as a liquid absorber in the packaging of fresh or frozen foods such as meat, poultry and seafood as well as fresh fruits and vegetables. Specific migration tests were not performed due to the high absorption of liquids by the substance. The Panel noted that if polya...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Safety assessment of the substance Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials

Published on: Wed, 07 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP Panel) assessed the safety of the additive Ln 1,4‐benzene dicarboxylic acid (with Ln = La, Eu, Gd, Tb) for use in food contact materials. It is a family of mixtures combining the four lanthanides lanthanum (La), europium (Eu), gadolinium (Gd) and/or terbium (Tb) in different proportions as their 1,4‐benzene dicarboxylate complexes, used as a taggant in plastics for authentication and ...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Bacillus subtilis (strain LMG S‐24584)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme endo‐1,4‐β‐xylanase (EC 3.2.1.8) is produced with the genetically modified Bacillus subtilis strain LMG S‐24584 by Puratos N. V. The genetic modifications do not give rise to safety concerns. The Panel noted that, although the production strain was not detected in the food enzyme, recombinant DNA was present in all batches of the food enzyme tested. The food enzyme is intended to be used in baking processes. Based on the maximum use levels re...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Safety evaluation of the food enzyme glucan 1,4‐α‐glucosidase from a genetically modified Aspergillus niger (strain NZYM‐BW)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucan 1,4‐α‐glucosidase (EC 3.2.1.3) is produced with the genetically modified Aspergillus niger strain NZYM‐BW by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. The glucan 1,4‐α‐glucosidase food enzyme is intended to be used in distilled alcohol production and starch processing for the production of glucose syrups. Residu...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Safety of the food enzyme glucoamylase from a genetically modified Aspergillus niger (strain NZYM‐BF)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme glucoamylase (glucan 1,4‐α‐glucosidase; EC 3.2.1.3) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This glucoamylase is intended to be used in brewing processes and in starch processing for glucose syrups production. Residual amounts of total organic s...

Europe - EFSA - European Food Safety Authority Publications

1-11-2018

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Safety evaluation of the food enzyme α‐amylase from a genetically modified Aspergillus niger (strain NZYM‐MC)

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The food enzyme alpha‐amylase (4‐α‐d‐glucan glucanohydrolase; EC 3.2.1.1) is produced with the genetically modified strain of Aspergillus niger by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This α‐amylase is intended to be used in starch processing for glucose syrups production, beverage alcohol (distilling) processes and baking proces...

Europe - EFSA - European Food Safety Authority Publications

31-10-2018

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos when used as a feed flavouring for all animal species

Published on: Tue, 30 Oct 2018 00:00:00 +0100 Following a request from the European Commission, the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and efficacy of a super critical carbon dioxide extract of Humulus lupulus L. flos (hop strobiles) when used as a sensory feed additive for all animal species. The additive is specified to containing 40% beta acids and less than 0.2% alpha acids. Known substances of conce...

Europe - EFSA - European Food Safety Authority Publications

26-10-2018

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Safety and efficacy of l‐threonine produced by fermentation using Escherichia coli CGMCC 7.232 for all animal species

Published on: Thu, 25 Oct 2018 00:00:00 +0200 The product subject of this assessment is l‐threonine produced by fermentation with a genetically modified strain of Escherichia coli (CGMCC 7.232). It is intended to be used in feed and water for drinking for all animal species and categories. The production strain and its recombinant DNA were not detected in the additive. The product l‐threonine, manufactured by fermentation with E. coli CGMCC 7.232, does not raise any safety concern with regard to the gen...

Europe - EFSA - European Food Safety Authority Publications

15-10-2018

Toy Land Company recalls Boom Boom ChemsSlime andPutty

Toy Land Company recalls Boom Boom ChemsSlime andPutty

Health Canada has determined that the slime and putty products do not meet the Canadian toy safety requirements related to boric acid content.

Health Canada

15-10-2018

Dollar Novelty (Karapelle Inc) recalls Barrel-O-Slime Toy

Dollar Novelty (Karapelle Inc) recalls Barrel-O-Slime Toy

Health Canada's sampling and evaluation program has determined the Barrel-O-Slime toy does not meet the Canadian toy safety requirements related to boric acid content.

Health Canada

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

3-10-2018

Inhibidores de la bomba de protones: evite el uso a largo plazo

  Prescrire, 1 de octubre de 2018 Los inhibidores de la bomba de protones (IBP), como el omeprazol, se utilizan en la esofagitis, los síntomas relacionados con el reflujo gastroesofágico y las úlceras pépticas. Tienen pocos efectos secundarios graves en el corto plazo. Pero este no es el caso a largo plazo: infecciones, fracturas, hiponatremia, etc. Pero la suspensión de un inhibidor de la bomba de protones se ve dificultado por un rebote de acidez, que a menudo conduce a una mayor ingesta de estos medi...

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

22-9-2018

Risk assessment of new sequencing information on genetically modified carnation FLO‐40689‐6

Risk assessment of new sequencing information on genetically modified carnation FLO‐40689‐6

Published on: Fri, 21 Sep 2018 00:00:00 +0200 The GMO Panel has previously assessed genetically modified (GM) carnation FLO‐40689‐6 and concluded that there is no scientific reason to consider that the import, distribution and retailing in the EU of carnation FLO‐40689‐6 cut flowers for ornamental use will cause any adverse effects on human health or the environment. On 27 October 2017, the European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for...

Europe - EFSA - European Food Safety Authority Publications

22-9-2018

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Published on: Fri, 21 Sep 2018 00:00:00 +0200 The GMO Panel has previously assessed genetically modified (GM) soybean BPS‐CV127‐9. This soybean was found to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 16 February 2018, European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soy...

Europe - EFSA - European Food Safety Authority Publications

10-9-2018

Kangaroo Manufacturing Inc. recalls Kangaroo's Super Cool Slime

Kangaroo Manufacturing Inc. recalls Kangaroo's Super Cool Slime

Health Canada's sampling and evaluation program has determined the Super Cool Slime products donot meet the Canadian toy safety requirements related to boric acid content.

Health Canada

14-8-2018

Genius Premium Craft Boxes recalls Do-It-Yourself Slime Kits

Genius Premium Craft Boxes recalls Do-It-Yourself Slime Kits

Health Canada’s sampling and evaluation program has determined the Do-It-Yourself Slime Kits do not meet the Canadian toy safety requirements related to boric acid content.

Health Canada

10-8-2018

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease

FDA approves new drug for treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for this rare, debilitating and often fatal genetic disease and the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment.

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

7-6-2018

Ovejoterapia: la nueva metodología que impacta física y cognitivamente en personas con discapacidad

Ovejoterapia: la nueva metodología que impacta física y cognitivamente en personas con discapacidad

“Las ovejas son una especie altamente social, superinteligentes, y son animales muy poco agresivos, por eso considerábamos que cumplían con requisitos mínimos para trabajar con niños en terapia, fue así como se nos ocurrió incluirlas en el trabajo terapéutico”, relata María José Ubilla, veterinaria, etóloga y coordinadora del Centro de Terapia Asistidas con Animales (CTAA) […]

Cuba - infomed - Red de Salud de Cuba

5-11-2018

EU/3/18/2070 (Accelsiors CRO and Consultancy Services Ltd)

EU/3/18/2070 (Accelsiors CRO and Consultancy Services Ltd)

EU/3/18/2070 (Active substance: (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid) - Orphan designation - Commission Decision (2018)7271 of Mon, 05 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/114/18

Europe -DG Health and Food Safety

30-10-2018

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Orphan Europe S.A.R.L.)

EU/3/18/2076 (Active substance: Glycine, L-alanine, L-arginine, L-aspartic acid, L-cysteine, L-cystine, L-glutamic acid, L-histidine, L-lysine monohydrate, L-methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, taurine) - Orphan designation - Commission Decision (2018)7277 of Tue, 30 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/100/18

Europe -DG Health and Food Safety

29-10-2018

Clopidogrel/Acetylsalicylic acid Zentiva (Sanofi-Aventis groupe)

Clopidogrel/Acetylsalicylic acid Zentiva (Sanofi-Aventis groupe)

Clopidogrel/Acetylsalicylic acid Zentiva (Active substance: clopidogrel / acetylsalicylic acid) - Centralised - 2-Monthly update - Commission Decision (2018)7249 of Mon, 29 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1144/WS1433/0051

Europe -DG Health and Food Safety

29-10-2018

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Sanofi Clir SNC)

DuoPlavin (Active substance: clopidogrel / acetylsalicylic acid) - Centralised - 2-Monthly update - Commission Decision (2018)7255 of Mon, 29 Oct 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1143/WS/1433/0050

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Actavis (Actavis Group PTC ehf.)

Zoledronic acid Actavis (Actavis Group PTC ehf.)

Zoledronic acid Actavis (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6488 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Voisin Consulting S.A.R.L.)

EU/3/16/1786 (Active substance: Recombinant adeno-associated viral vector serotype 2 carrying the gene for the human aromatic L-amino acid decarboxylase protein) - Transfer of orphan designation - Commission Decision (2018)6427 of Tue, 02 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/183/16/T/02

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Mylan (Mylan S.A.S.)

Zoledronic acid Mylan (Mylan S.A.S.)

Zoledronic acid Mylan (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6486 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

2-10-2018

Zoledronic acid Teva (Teva B.V.)

Zoledronic acid Teva (Teva B.V.)

Zoledronic acid Teva (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)6466 of Tue, 02 Oct 2018

Europe -DG Health and Food Safety

1-10-2018

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Pharma Gateway AB)

EU/3/16/1762 (Active substance: Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker) - Transfer of orphan designation - Commission Decision (2018)6399 of Mon, 01 Oct 2018 European Medicines Agency (EMA) procedure number: EMA/OD/107/16/T/01

Europe -DG Health and Food Safety

24-9-2018

Zoledronic acid Hospira (Pfizer Europe MA EEIG)

Zoledronic acid Hospira (Pfizer Europe MA EEIG)

Zoledronic acid Hospira (Active substance: zoledronic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6243 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2365/T/33

Europe -DG Health and Food Safety

28-8-2018

EU/3/18/2056 (Nogra Pharma Limited)

EU/3/18/2056 (Nogra Pharma Limited)

EU/3/18/2056 (Active substance: (S)-(-)-3-(4-aminophenyl)-2-methoxypropanoic acid) - Orphan designation - Commission Decision (2018)5728 of Tue, 28 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/075/18

Europe -DG Health and Food Safety

6-8-2018

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Accord Healthcare Limited)

Zoledronic acid Accord (Active substance: zoledronic acid) - Centralised - Yearly update - Commission Decision (2018)5386 of Mon, 06 Aug 2018

Europe -DG Health and Food Safety

1-8-2018

Ucedane (Lucane Pharma)

Ucedane (Lucane Pharma)

Ucedane (Active substance: carglumic acid) - Centralised - Yearly update - Commission Decision (2018)5230 of Wed, 01 Aug 2018

Europe -DG Health and Food Safety

27-7-2018

EU/3/17/1932 (Millendo Therapeutics SAS)

EU/3/17/1932 (Millendo Therapeutics SAS)

EU/3/17/1932 (Active substance: Synthetic cyclic 8 amino acid analogue of human unacylated ghrelin) - Transfer of orphan designation - Commission Decision (2018)5049 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/066/17/T/01

Europe -DG Health and Food Safety

11-7-2018

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Merck Sharp and Dohme B.V.)

Vantavo (Active substance: alendronic acid / colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4511 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1180/T/30

Europe -DG Health and Food Safety

3-7-2018

Granupas (Eurocept International B.V.)

Granupas (Eurocept International B.V.)

Granupas (Active substance: Para-aminosalicylic acid) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4256 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2709/T/25

Europe -DG Health and Food Safety

27-6-2018

EU/3/11/849 (Merck Sharp and Dohme B.V.)

EU/3/11/849 (Merck Sharp and Dohme B.V.)

EU/3/11/849 (Active substance: (S)-{8-fluoro-2-2[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-3,4-dihydro-4-quinazolinyl} acetic acid) - Transfer of orphan designation - Commission Decision (2018)4102 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/090/10/T/02

Europe -DG Health and Food Safety

19-6-2018

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Dany Bienenwohl GmbH)

Dany's BienenWohl (Active substance: oxalic acid dihydrate) - Centralised - Authorisation - Commission Decision (2018)3892 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/4667

Europe -DG Health and Food Safety